Si-Yang Liu

List of Publications by Year
in descending order

25 papers	1,088 citations	759233 12 h-index	642732 23 g-index
26 all docs	26 docs citations	26 times ranked	1222 citing authors

#	Article	IF	Citations
1	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology, 2017, 6, e1356145.	4.6	305
2	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Journal of Clinical Oncology, 2021, 39, 713-722.	1.6	159
3	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. Journal of Thoracic Oncology, 2018, 13, 1668-1675.	1.1	111
4	Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine, 2020, 60, 102990.	6.1	95
5	Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2022, 12, 1690-1701.	9.4	84
6	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer, 2018, 125, 86-92.	2.0	63
7	Genomic signatures define three subtypes of EGFR-mutant stage IIâ€“III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications, 2021, 12, 6450.	12.8	48
8	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opinion on Investigational Drugs, 2020, 29, 1355-1364.	4.1	39
9	Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomarker Research, 2020, 8, 22.	6.8	37
10	Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. Translational Oncology, 2021, 14, 100921.	3.7	34
11	Predictive value of TCR Vî²-Jî² profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight, 2022, 7, .	5.0	17
12	Perioperative targeted therapy for oncogene-driven NSCLC. Lung Cancer, 2022, 172, 160-169.	2.0	15
13	Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 589-599.	2.4	13
14	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. JTO Clinical and Research Reports, 2022, 3, 100257.	1.1	11
15	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). JTO Clinical and Research Reports, 2022, 3, 100261.	1.1	9
16	Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced nonâ€“small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).. Journal of Clinical Oncology, 2022, 40, 9032-9032.	1.6	9
17	Poor prognosis of intraâ€tumoural TRBV6â€6 variants in EGFRâ€mutant NSCLC: Results from the ADJUVANTâ€CTONG1104 trial. Clinical and Translational Medicine, 2022, 12, e775.	4.0	8
18	Toward a cure for lung cancer: important advances in operable non-small cell lung cancer. Science Bulletin, 2022, 67, 1402-1405.	9.0	8

#	Article	IF	Citations
19	Concomitant genetic alterations having greater impact on the clinical benefit of EGFRâ€TKIs in EGFR â€mutant advanced NSCLC than BIM deletion polymorphism. Clinical and Translational Medicine, 2020, 10, 337-345.	4.0	7
20	What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 217-220.	1.6	6
21	Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score. Translational Oncology, 2022, 15, 101254.	3.7	4
22	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Nonâ€“Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705). Clinical Lung Cancer, 2022, 23, e395-e399.	2.6	4
23	Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations. Journal of Thoracic Oncology, 2021, 16, 712-714.	1.1	1
24	Predictive value of intraâ€tumoural TCRÎ² rearrangements in precisely selecting adjuvant therapy for EGFR â€mutant nonâ€smallâ€cell lung cancer. Clinical and Translational Discovery, 2022, 2, .	0.5	1
25	Efficacy of immune checkpoint inhibitors in patients with nonâ€“small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertions.. Journal of Clinical Oncology, 2022, 40, 2591-2591.	1.6	0